PRO MEDICUS LIMITED — Interim / Quarterly Report 2017

Aug 17, 2017

Appendix 4E Preliminary Final Report

Rule 4.2A

Appendix 4E Preliminary Final Report

1. Company details

Name of entity

. Company details ame of entity	. Company details ame of entity
Pro Medicus Limited
ABN or equivalent company reference Financial year ended (‘current period’) 25 006 194 752 30 June 2017 . Results for announcement to the market		Financial year ended (‘current period’)			Financial year ended (‘previous period’)
		30 June 2017			30 June 2016
ASX Listing Rules **Ref **				2017 A$’000		2016 A$’000		% change
2.1	Revenue from continuing operations			31,619		27,577		14.7%
2.2 2.3	Underlying Profit after Tax (minus currency gains/(losses) Currency gains/(losses) after tax Profit/(Loss) from ordinary activities after tax attributable to members			9,865 (544) 9,321		6,431 (63) 6,368		53.4% N/A 46.4%
	Net Profit/(Loss) for the period attributable to members			9,321 Up 46.4%
	% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.
2.4	Dividends (distributions)			Amount per security			Franked/Unfranked amount per security
	Dividend amount per security Final Dividend (franked) Interim dividend (unfranked)			2.5 cents 1.5 cents			2.5 cents 1.5 cents
2.5	Record date for Final dividends			8 September 2017
	Payment date for Final dividends			28 September 2017

Appendix 4E Page 1

Appendix 4E Preliminary Final Report

	2.6		Australia The Group’s Australian employees undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions. The Group’s Australian revenue was 28.6% above last year as a result of new sales of both the Visage PACS and Visage RIS products with a number of sales being for the combined product offering. Promedicus.net, the company’s e-health offering, continued to hold its market position despite increasing competition. North America The growing North American team fulfil sales, marketing and professional services roles. Revenue from North America increased by 27.6% compared to the previous year. This was largely attributable to new sales and an increase in transaction based revenue from sales of Visage technology as more contracts came on stream. Europe The Group’s employees in its Berlin office undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the Group's European operations. Revenue from our European operations decreased by 58.2% from last year, due to a large capital sale to a German government hospital in the prior year Financials Reported profit after tax for the period was $9.32m an increase of $2.95m (46.4%) from the previous year. Full year revenue of the Group increased from $27.58m to $31.62m, an increase of 14.7%. The key drivers of the profit increase was the significant increase in the performance of the North American and Australian operations. As the Group’s costs are relatively fixed, an increase in sales has a significant impact on profitability. As a result, it is anticipated that the 2018 financial year will show a continuing improvement in operational results, however this is dependent upon many market factors over which the Directors have limited or no control. Shareholder Returns The directors are confident that the holdings of reserve cash are sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.
	3.		Statement of Comprehensive Income Please refer to the Statement of Comprehensive Income in the attached Financial Statements.
	4.		Statement of Financial Position Pleasereferto the Statement of Financial Position inthe attachedFinancialStatements.
	5.		Statement of cash flows Pleasereferto the Statement ofcash flowsinthe attachedFinancialStatements.

Appendix 4E Page 2

Appendix 4E Preliminary Final Report

		Appendix 4E Preliminary Final Report
	6.	Details of Dividends 2017 $’000 2016 $’000 Final Dividend A franked Final Dividend of 2.5 cents (2016: 1.5 cents) per share will be paid on 28 September 2017. 2,567 1,535 Current Year Interim An unfranked Interim Dividend of 1.5 cents (2016: 1.5 cents) per share was paid on 24 March 2017. 1,540 1,526 No foreign sourced dividend or distribution is included in either the interim or final dividends.
	7.	Dividend or Distribution reinvestment plans There are no dividend or distribution reinvestment plans in operation.
	8.	Statement of Retained Earnings Please refer to Statement of Changes in Equity in the attached Financial Statements.
	9.	Net Tangible Assets per security 2017 2016 Net Tangible Assets per security $0.23 $0.17
	10.	Details of entities over which control has been gained or lost during the period There are no entities over which control has been gained or lost during the period
	11.	Associates and joint venture entities There are no associates or joint venture entities
	12.	Other significant information needed by an investor to make an informed assessment of the entity’s financial performance and financial position. Please refer to section 2.6
	13.	Foreign Entity accounting standards Australian Accounting Standards &International Financial Reporting Standards

Appendix 4E Page 3

Appendix 4E Preliminary Final Report

14. Commentary on results for the period. The earnings per security and the nature of any dilution aspects . Please refer to Note 8 of the attached Financial Statements.

Returns to shareholders including distributions and buy backs. Please refer to Note 9 of the attached Financial Statements.

Significant features of operating performance . Please refer to section 2.6.

The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.

Discussion of trends in performance. Please refer to section 2.6.

15. Audit Statement

This report is based on accounts to which one of the following applies. (Tick one)

 The +accounts have been  The[+] accounts have been subject to audited. review. [The ] +accounts are in the [The ][+][accounts have ] [not][yet][been ] process of being audited. audited or reviewed.

Sign here:

Date: 18 August 2017

==> picture [209 x 68] intentionally omitted <==

Print name: Sam Hupert Chief Executive Officer

Appendix 4E Page 4